专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2004089905A1 N-[(PIPERAZINYL)HETARYL]ARYLSULFONAMIDE COMPOUNDS WITH AFFINITY FOR THE DOPAMINE D3 RECEPTOR 审中-公开
标题翻译： N - [（PIPERAZINYL）HETARYL]具有多巴胺D3受体亲和性的芳香酰胺化合物
公开(公告)号：WO2004089905A1
公开(公告)日：2004-10-21
申请号：PCT/EP2004/003872
申请日：2004-04-13
申请人： ABBOTT GMBH & CO. KG , BRAJE, Wilfried , HAUPT, Andreas , LUBISCH, Wilfried , GRANDEL, Roland , DRESCHER, Karla , GENESTE, Hervé , UNGER, Liliane , SAUER, Daryl, R. , TURNER, Sean, C.
发明人： BRAJE, Wilfried , HAUPT, Andreas , LUBISCH, Wilfried , GRANDEL, Roland , DRESCHER, Karla , GENESTE, Hervé , UNGER, Liliane , SAUER, Daryl, R. , TURNER, Sean, C.
IPC分类号： C07D213/76
CPC分类号： C07D213/74 , C07D213/76 , C07D239/48 , C07D239/50 , C07D403/04 , C07D403/14 , C07D487/08
摘要： The invention relates to N-[(piperazinyl)hetaryl]arylsulfonamide compounds of the general formula (I ) in which Q is a bivalent, 6-membered heteroaromatic radical which possesses 1 or 2 N atoms as ring members and which optionally carries one or two substituents R a which is/are selected, independently of each other, from halogen, CN, NO 2 , C0 2 R 4 , COR 5 , C 1 -C 4 -alkyl and C 1 -C 4 -haloalkyl; Ar is phenyl or a 6-membered heteroaromatic radical which possesses 1 or 2 N atoms as ring members and which optionally carries one or two substituents R b , which is/are selected from halogen, NO 2 , CN, C0 2 R 4 , COR 5 , C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, C 3 -C 6 -cycloalkyl, C 3 -C 6 -cycloalkyl-C 1 -C 4 -alkyl and C 1 -C 4 -haloalkyl, with it also being possible for two radicals R b which are bonded to adjacent C atoms of Ar to be together C 3 -C 4 -alkylene; R 1 is hydrogen, C 1 -C 4 -alkyl, C 1 -C 4 -haloalkyl, C 3 -C 6 -cycloalkyl, C 3 -C 6 -cycloalkyl-C 1 -C 4 -alkyl, C 1 -C 4 -hydroxyalkyl, C 1 -C 4 -alkoxy-C 1 -C 4 -alkyl, C 3 -C 4 -alkenyl or C 3 -C 4 -alkynyl; with the radicals n, R 1 , R 2 , R 3 , R 4 and R 5 having the meanings given in the patent claims, to the N-oxides and to the physiologically tolerated acid addition salts of these compounds and to pharmaceutical compositions which comprise at least one N-[(piperazinyl)hetaryl]arylsulfonamide compound as claimed in one of claims 1 to 10 and/or at least one physiologically tolerated acid addition salt of I and/or an N-oxide of I, where appropriate together with physiologically acceptable carriers and/or auxiliary substances for treating diseases which respond to influencing by dopamine D 3 receptor antagonists or agonists, in particular for treating diseases of the central nervous system and disturbances of kidney function.
摘要翻译：本发明涉及通式（I）的N - [（哌嗪基）杂芳基]芳基磺酰胺化合物，其中Q是具有1或2个N原子作为环成员的二价，6元杂芳族基团，并且任选地带有一个或两个取代基R a彼此独立地选自卤素，CN，NO 2，CO 2 R 4，COR 5，C 1 -C 4烷基和C 1 -C 4卤代烷基; Ar是苯基或6元杂芳族基，其具有1或2个N原子作为环成员，并且任选地带有一个或两个选自卤素，NO 2，CN，CO 2 R 4， COR 5，C 1 -C 6 - 烷基，C 2 -C 6 - 烯基，C 2 -C 6 - 炔基，C 3 -C 6 - 环烷基，C 3 -C 6 - 环烷基-C 1 -C 4烷基和C 1 -C 4卤代烷基，对于与Ar的相邻C原子键合在一起为C 3 -C 4亚烷基的两个基团R b是可能的; R 1是氢，C 1 -C 4烷基，C 1 -C 4卤代烷基，C 3 -C 6环烷基，C 3 -C 6环烷基-C 1 -C 4烷基，C 1 -C 4羟烷基，C 1 -C 4烷氧基-C 1 C 1-4 - 烷基，C 3 -C 4 - 烯基或C 3 -C 4 - 炔基; 具有如专利权利要求中给出的含义的基团n，R 1，R 2，R 3，R 4和R 5与N-氧化物和生理上耐受的酸添加这些化合物的盐和包含至少一种如权利要求1至10中任一项所述的N - [（哌嗪基）杂芳基]芳基磺酰胺化合物和/或至少一种I和/或N的生理上耐受的酸加成盐的药物组合物氧化物，其中适当地与生理上可接受的载体和/或辅助物质一起用于治疗对由多巴胺D3受体拮抗剂或激动剂影响的疾病，特别是用于治疗中枢神经系统疾病和肾功能紊乱。

2. 发明申请

WO2005058328A1 TETRAHYDROBENZAZEPINES AND THEIR USE IN THE MODULATION OF THE DOPAMINE D3 RECEPTOR 审中-公开
标题翻译：四氢苯并噻嗪及其在多巴胺D3受体调节中的应用
公开(公告)号：WO2005058328A1
公开(公告)日：2005-06-30
申请号：PCT/EP2004/014428
申请日：2004-12-17
申请人： ABBOTT GMBH & CO. KG , BRAJE, Wilfried , HAUPT, Andreas , LUBISCH, Wilfried , GRANDEL, Roland , DRESCHER, Karla , GENESTE, Hervé , UNGER, Liliane , SAUER, Daryl, R.
发明人： BRAJE, Wilfried , HAUPT, Andreas , LUBISCH, Wilfried , GRANDEL, Roland , DRESCHER, Karla , GENESTE, Hervé , UNGER, Liliane , SAUER, Daryl, R.
IPC分类号： A61K31/55
CPC分类号： C07D223/16 , C07D409/12
摘要： The invention relates to tetrahydrobenzazepines of the general formula (I) in which the variables Ar, A, B, Y, R 1 and R 2 have the meanings indicated in claim 1, as well as the N-oxides of these compounds, the physiologically tolerated acid addition salts of these compounds and the physiologically tolerated acid addition salts of the N-oxides. The invention also relates to a pharmaceutical composition that comprises at least one tetrahydrobenzazepine compound of the formula (I), the physically tolerated acid addition salt of (I), the N-oxide of compound of the formula (I) and/or the physically tolerated acid addition salts of the N-oxides of (I), and further to the use of a compound according to the present invention for treating disorders that respond beneficially to dopamine D 3 receptor antagonists or dopamine D 3 agonists. The compounds according to the invention are preferably useful for the treatment of disorders of the central nervous system such as schizophrenia and depression and for the treatment of renal function disorders.
摘要翻译：本发明涉及通式（I）的四氢苯并吖庚因，其中变量Ar，A，B，Y，R 1和R 2具有权利要求1中所示的含义，以及这些的N-氧化物化合物，这些化合物的生理上耐受的酸加成盐和N-氧化物的生理上耐受的酸加成盐。本发明还涉及药物组合物，其包含至少一种式（I）的四氢苯并氮杂化合物，（I）的物理耐受的酸加成盐，式（I）化合物的N-氧化物和/或物理（I）的N-氧化物的耐受的酸加成盐，并且还涉及使用根据本发明的化合物治疗有益于多巴胺D3受体拮抗剂或多巴胺D3激动剂的病症。根据本发明的化合物优选可用于治疗中枢神经系统疾病如精神分裂症和抑郁症以及治疗肾功能障碍。

3. 发明申请

WO2006015842A1 4-PIPERAZINYL-PYRIMIDINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR 审中-公开
标题翻译：适用于治疗多巴胺D3受体调节障碍的4-哌啶子基吡啶化合物
公开(公告)号：WO2006015842A1
公开(公告)日：2006-02-16
申请号：PCT/EP2005/008592
申请日：2005-08-08
申请人： ABBOTT GMBH & CO. KG , HAUPT, Andreas , UNGER, Liliane , DRESCHER, Karla , JONGEN-RELO, Ana, Lucia , GRANDEL, Roland , BRAJE, Wilfried , GENESTE, Hervé
发明人： HAUPT, Andreas , UNGER, Liliane , DRESCHER, Karla , JONGEN-RELO, Ana, Lucia , GRANDEL, Roland , BRAJE, Wilfried , GENESTE, Hervé
IPC分类号： C07D417/12
CPC分类号： C07D239/42 , C07D239/52 , C07D239/56 , C07D401/12 , C07D403/12 , C07D417/12
摘要： The present invention relates to novel 4-piperazinylpyrimidine compounds. The compounds possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of the dopamine D 3 receptor. The 4 piperzinylpyrimidine compounds have the general formula (I), wherein Ar, X, A, R 1 and R 1a are as defined in the claims.
摘要翻译：本发明涉及新的4-哌嗪基嘧啶化合物。该化合物具有有价值的治疗性质，特别适用于治疗对多巴胺D 3受体调节作出反应的疾病。 4个哌嗪基嘧啶化合物具有通式（I），其中Ar，X，A，R 1和R 1a如权利要求中所定义。

4. 发明申请

WO2006040182A1 HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR 审中-公开
标题翻译：适用于治疗多巴胺D3受体调节障碍的异种化合物
公开(公告)号：WO2006040182A1
公开(公告)日：2006-04-20
申请号：PCT/EP2005/011106
申请日：2005-10-14
申请人： ABBOTT GMBH & CO. KG , DRESCHER, Karla , HAUPT, Andreas , UNGER, Liliane , TURNER, Sean, C. , BRAJE, Wilfried , GRANDEL, Roland , HENRY, Christophe , BACKFISCH, Gisela , BEYERBACH, Armin , LUBISCH, Wilfried
发明人： DRESCHER, Karla , HAUPT, Andreas , UNGER, Liliane , TURNER, Sean, C. , BRAJE, Wilfried , GRANDEL, Roland , HENRY, Christophe , BACKFISCH, Gisela , BEYERBACH, Armin , LUBISCH, Wilfried
IPC分类号： C07D207/09 , C07D401/12 , C07D405/12 , C07D409/12 , C07D401/04 , C07D403/04 , C07D413/12 , C07D205/04 , C07D413/10 , C07D413/14 , C07D211/28 , A61K31/397 , A61K31/445 , A61P25/16
CPC分类号： C07D413/14 , C07D205/04 , C07D207/09 , C07D211/28 , C07D401/04 , C07D401/12 , C07D403/04 , C07D405/12 , C07D409/12 , C07D413/10 , C07D413/12
摘要： The invention relates to compounds of the formula (I) wherein n is 0, 1 or 2; G is CH 2 or CHR 3 ; R 1 is H, C,-C 6 -alkyl, C,-C 6 -alkyl substituted by C 3 -C 6 -cycloalkyl, C l -C 6 -hydroxyalkyl, fluorinated C,-C 6 -alkyl, C 3 -C 6 -cycloalkyl, fluorinated C 3 -C 6 -cycloalkyl, C 3 -C 6 alkenyl, fluorinated C 3 -C 6 -alkenyl, formyl, acetyl or propionyl; R 2 , R 3 and R 4 are, independently of each other, H, methyl, fluoromethyl, difluoromethyl, or trifluoromethyl; A is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one ore more substituents selected from halogen, methyl, methoxy and CF 3 ; E is NR 5 or CH 2 , wherein R 5 is H or C 1 -C 3 -alkyl; Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6- membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR 8 , where R 8 is H, C 1 -C 4 -alkyl, fluorinated C 1 -C 4 -alkyl, C 1 -C 4 alkylcarbonyl or fluorinated C 1 -C 4 -alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents R a , wherein the variable R a has the meanings given in the claims and in the description; and physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.
摘要翻译：本发明涉及式（I）化合物，其中n为0,1或2; G是CH

5. 发明申请

WO2009056625A1 1,2,4,-TRIAZIN-3,5-DIONE COMPOUNDS FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR 审中-公开
标题翻译： 1,2,4，-TRIAZIN-3,5-Dipone化合物，用于治疗多巴胺D3受体调节症状
公开(公告)号：WO2009056625A1
公开(公告)日：2009-05-07
申请号：PCT/EP2008/064795
申请日：2008-10-31
申请人： ABBOTT GMBH & CO. KG , BRAJE, Wilfried , TURNER, Sean Colm , HAUPT, Andreas , LANGE, Udo , GENESTE, Hervé , DRESCHER, Karla , UNGER, Liliane , JONGEN-RELO, Ana Lucia , BESPALOV, Anton
发明人： BRAJE, Wilfried , TURNER, Sean Colm , HAUPT, Andreas , LANGE, Udo , GENESTE, Hervé , DRESCHER, Karla , UNGER, Liliane , JONGEN-RELO, Ana Lucia , BESPALOV, Anton
IPC分类号： C07D403/12 , A61K31/53 , A61P25/00 , A61P25/18 , A61P25/30
CPC分类号： C07D403/12
摘要： The invention relates to compounds of the formula (I), wherein A is a saturated or unsaturated hydrocarbon chain having a chain length of 4 to 6 carbon atoms, the hydrocarbon chain being unsubstituted or substituted by 1, 2 or 3 methyl groups; R 1 is selected from the group consisting of hydrogen, C 1 -C 3 alkyl and fluorinated C 1 -C 3 alkyl; R 2 is hydrogen, halogen, cyano, C 1 -C 3 alkyl, C 1 -C 3 alkoxy, fluorinated C 1 -C 3 alkyl or fluorinated C 1 -C 3 alkoxy; R 3 is selected from the group consisting of branched C 4 -C 6 alkyl and C 3 -C 6 cycloalkyl, and R 4 is C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, fluorinated C 1 -C 3 alkyl and fluorinated C 3 -C 6 cycloalkyl. and the physiologically tolerated salts of these compounds and the N-oxides thereof. The invention also relates to a pharmaceutical composition that comprises at least one compound of the formula (I) and/or at least one physiologically tolerated acid addition salt thereof, and furtherto amethod for treating disorders that respond beneficially to dopamine D 3 receptor antagonists or dopamine D 3 agonists, said method comprising administering an effective amount of at least one compound or physiologically tolerated acid addition salt of the formula (I) to a subject in need thereof.
摘要翻译：本发明涉及式（I）化合物，其中A是链长为4-6个碳原子的饱和或不饱和烃链，该烃链未被取代或被1,2或3个甲基取代; R1选自氢，C1-C3烷基和氟化C1-C3烷基; R2是氢，卤素，氰基，C1-C3烷基，C1-C3烷氧基，氟化C1-C3烷基或氟化C1-C3烷氧基; R3选自支链C 4 -C 6烷基和C 3 -C 6环烷基，且R 4为C 1 -C 6烷基，C 3 -C 6环烷基，氟化C 1 -C 3烷基和氟化C 3 -C 6环烷基。以及这些化合物的生理上耐受的盐及其N-氧化物。本发明还涉及包含至少一种式（I）化合物和/或其至少一种生理上耐受的酸加成盐的药物组合物，还涉及用于治疗有益于多巴胺D3受体拮抗剂或多巴胺D3拮抗剂的病症的方法，所述方法包括向有需要的受试者施用有效量的至少一种式（I）的化合物或生理学上耐受的酸加成盐。

6. 发明申请

WO2006040180A1 AMINOMETHYL SUBSTITUTED BICYCLIC AROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR 审中-公开
标题翻译：适用于治疗多巴胺D3受体调节障碍的氨基甲酸替代双相芳族化合物
公开(公告)号：WO2006040180A1
公开(公告)日：2006-04-20
申请号：PCT/EP2005/011093
申请日：2005-10-14
申请人： ABBOTT GMBH & CO. KG , DRESCHER, Karla , HAUPT, Andreas , UNGER, Liliane , TURNER, Sean, C. , BRAJE, Wilfried , GRANDEL, Roland
发明人： DRESCHER, Karla , HAUPT, Andreas , UNGER, Liliane , TURNER, Sean, C. , BRAJE, Wilfried , GRANDEL, Roland
IPC分类号： C07C317/34 , C07D209/14 , C07D209/62 , C07D235/14 , A61K31/136 , A61P25/00 , A61K31/145 , A61K31/403 , A61K31/407 , A61K31/4174
CPC分类号： C07D471/04 , C07D209/14 , C07D209/62 , C07D235/14
摘要： The present invention relates to an aminomethyl substituted bicyclic aromatic compound of the formula (I) wherein Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6-membered C-bound heteroaromatic radical comprising as ring member 1, 2 or 3 heteroatoms which are, independently of each other, selected from O, S and N, and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR 8 , where R 8 is H, C 1 -C 4 -alkyl, fluorinated C 1 -C 4 -alkyl, C 1 -C 4 -alkylcarbonyl or fluorinated C 1 -C 4 -alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents R a , wherein the variable R a has the meanings given in the claims and in the description; X is a covalent bond or N-R 2 , CHR 2 , CHR 2 CH 2 , N or C-R 2 ; Y is N-R 2a , CHR 2a , CHR 2a CH 2 or CHR 2a CH 2 CH 2 ; is a single bond or a double bond; E is CH 2 or NR 3 ; R 1 is H, C 1 -C 4 -alkyl, C 3 -C 4 -cycloalkyl, C 3 -C 4 -cycloalkylmethyl, C 3 -C 4 -alkenyl, fluorinated C 1 -C 4 -alkyl, fluorinated C 3 -C 4 -cycloalkyl, fluorinated C 3 -C 4 -cycloalkylmethyl, fluorinated C 3 -C 4 -alkenyl, formyl or C 1 -C 3 -alkylcarbonyl; R 1a is H, C 1 -C 4 -alkyl, C 3 -C 4 -cycloalkyl, C 3 -C 4 -alkenyl, fluorinated C 1 -C 4 -alkyl, fluorinated C 3 -C 4 -cycloalkyl, fluorinated C 3 -C 4 -alkenyl, R 2 and R 2a each independently are H, CH 3 , CH 2 F, CHF 2 or CF 3 or R 1a and R 2 or R 1a and R 2a together are (CH 2 ) n with n being 1, 2 or 3; R 3 is H or C 1 -C 4 -alkyl; R 4 and R 5 independently of each other are H, C 1 -C 4 -alkyl, fluorinated C 1 -C 4 -alkyl or C 1 -C 4 -alkoxy or may form, together with N, a 4-, 5- or 6-membered saturated or unsaturated ring; R 6 and R 7 independently of each other are H or halogen; and the physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula (I) or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.
摘要翻译：本发明涉及式（I）的氨基甲基取代的双环芳族化合物，其中Ar是选自苯基，5-或6-元C-结合的杂芳族基团的环状基团，其包含作为环成员1,2 或3个彼此独立地选自O，S和N的杂原子和稠合于饱和或不饱和的5-或6-元碳环或杂环的苯环，其中杂环包含作为环成员1， 2或3个选自N，O和S的杂原子和/或1,2或3个含杂原子的基团，各自独立地选自NR 8，其中R 8是H， C 1 -C 4 - 亚烷基，氟化C 1 -C 4 - 烷基，C 1 -C 1-4烷基，C 1 -C 4烷基，C 1 -C 4 - 其中环状基团Ar可以带有1个碳原子的烷基羰基或氟化C 1 -C 4 - 烷基羰基， 2或3个取代基R a a，其中变量R a a具有在声明和说明书; X是共价键或NR 2，CHR 2，CHR 2 CH 2，N或CR ^{2 ; Y是NR 2a，CHR 2，H 2，CH 2，CH 2或CHR 2 O 2， CH _{2 CH _{2 ; 是单键或双键; E是CH 2或NR 3; R 1是H，C 1 -C 4 - 烷基，C 3 -C 4 - C 3 -C 4 - 环烷基甲基，C 3 -C 4 - 亚烷基，C 3 -C 4 - 环烷基，C 3 -C 4 - 氟化C 1 -C 4 - 亚烷基，氟化C 3 -C 4 - 环烷基，氟化C _{-C _{3 - 烷基羰基; R 1a是H，C 1 -C 4 - 烷基，C 3 -C 4烷基， C 3 -C 4 - 亚烷基，氟化C 1 -C 4 - 亚烷基，C 3 -C 4 - 氟化C 3 -C 4 - 环烷基，氟化C 3 -C 4 - 亚烯基，R SUP > 2和R 2a各自独立地为H，CH 3，CH 2，F，CHF 2， >或CF 3或R 1a和R 2或R 1a和R 2a和R 2b 一起是n为1,2或3的（CH 2）2 n。 R 3是H或C 1 -C 4 - 烷基; R 4和R 5彼此独立地为H，C 1 -C 4 - 烷基，氟化C C 1 -C 4 - 烷基或C 1 -C 4 - 烷氧基，或者可以与N， 4-，5-或6-元饱和或不饱和环; R 6和R 7彼此独立地为H或卤素; 及其生理上耐受的酸加成盐。本发明还涉及式（I）化合物或其药学上可接受的盐在制备用于治疗易受多巴胺D3受体配体治疗的医学疾病的药物组合物中的用途。}}}}}

7. 发明申请

WO2004108706A1 TRIAZOLE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR 审中-公开
标题翻译：适用于治疗多巴胺D3受体调节症状的三唑化合物
公开(公告)号：WO2004108706A1
公开(公告)日：2004-12-16
申请号：PCT/EP2004/006139
申请日：2004-06-07
申请人： ABBOTT GMBH & CO. KG , HAUPT, Andreas , GRANDEL, Roland , BRAJE, Wilfried , GENESTE, Hervé , DRESCHER, Karla , STARCK, Dorothea , TESCHENDORF, Hans-Jürgen
发明人： HAUPT, Andreas , GRANDEL, Roland , BRAJE, Wilfried , GENESTE, Hervé , DRESCHER, Karla , STARCK, Dorothea , TESCHENDORF, Hans-Jürgen
IPC分类号： C07D403/12
CPC分类号： C07D403/12
摘要： The invention relates to triazole compounds of the general formula I wherein R 1 is hydrogen or methyl, and R 2 is C 3 -C 4 alkyl or C 1 -C 2 fluoroalkyl, as well as the physiologically tolerated acid addition salts of these compounds. The invention also relates to a pharmaceutical composition that comprises at least one triazole compound of the formula (I) and/or at least one physiologically tolerated acid addition salt thereof, and further to a method for treating disorders that respond beneficially to dopamine D 3 receptor antagonists or dopamine D 3 agonists, said method comprising administering an effective amount of at least one triazole compound or physiologically tolerated acid addition salt of the formula (I) to a subject in need thereof.
摘要翻译：本发明涉及通式Ⅰ的三唑化合物，其中R 1为氢或甲基，R 2为C 3 -C 4烷基或C 1 -C 2氟烷基，以及这些化合物的生理上耐受的酸加成盐。本发明还涉及包含至少一种式（I）的三唑化合物和/或至少一种生理上耐受的酸加成盐的药物组合物，还涉及治疗有益于多巴胺D3受体拮抗剂的病症的方法或多巴胺三角体，所述方法包括向有需要的受试者施用有效量的至少一种式（I）的三唑化合物或生理学上耐受的酸加成盐。

8. 发明申请

WO2006040179A1 AMINOETHYLAROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR 审中-公开
标题翻译：适用于治疗多巴胺D3受体调节障碍的氨基甲醛化合物
公开(公告)号：WO2006040179A1
公开(公告)日：2006-04-20
申请号：PCT/EP2005/011092
申请日：2005-10-14
申请人： ABBOTT GMBH & CO. KG , DRESCHER, Karla , HAUPT, Andreas , UNGER, Liliane , TURNER, Sean, C. , BRAJE, Wilfried , GRANDEL, Roland
发明人： DRESCHER, Karla , HAUPT, Andreas , UNGER, Liliane , TURNER, Sean, C. , BRAJE, Wilfried , GRANDEL, Roland
IPC分类号： C07C311/29 , C07C311/21 , C07D213/76 , C07D207/09 , C07C317/22 , C07C317/14 , A61K31/18 , A61K31/44 , A61P25/18
CPC分类号： C07D213/76 , C07C311/21 , C07C311/29 , C07C2601/02 , C07D207/09
摘要： The present invention relates to aromatic compounds of the formula (I) wherein Ar is phenyl or an aromatic 5- or 6-membered C-bound heteroaromatic radical, wherein Ar may carry 1 radical R a and wherein Ar may also carry 1 or 2 radicals R b ; X is N or CH; E is CR 6 R 7 or NR 3 ; R 1 is C 1 -C 4 -alkyl, C 3 -C 4 -cycloalkyl, C 3 -C 4 -cycloalkylmethyl, C 3 -C 4 -alkenyl, fluorinated C l -C 4 -alkyl, fluorinated C 3 -C 4 -cycloalkyl, fluorinated C 3 -C 4 -cycloalkylmethyl, fluorinated C 3 -C 4 -alkenyl, formyl or C 1 -C 3 -alkylcarbonyl; R 1a is H, C 1 -C 4 -alkyl, C 3 -C 4 -cycloalkyl, C 3 -C 4 -cycloalkylmethyl, C 3 -C 4 -alkenyl, fluorinated C 1 -C 4 -alkyl, fluorinated C 3 -C 4 -cycloalkyl, fluorinated C 3 -C 4 -cycloalkylmethyl, fluorinated C 3 -C 4 -alkenyl, or R 1a and R 2 together are (CH 2 ) n with n being 2, 3 or 4, or R 1a and R 2a together are (CH 2 ) n with n being 2, 3 or 4; R 2 and R 2a are independently of each other H, C 1 -C 4 -alkyl or fluorinated C 1 -C 4 -alkyl or R 2a and R 2 together are (CH 2 ) m with m being 1, 2, 3, 4 or 5; R 3 is H or C 1 -C 4 -alkyl; R 6 , R 7 independently of each other are selected from H, fluorine, C 1 -C 4 -alkyl and fluorinated C 1 -C 4 -alkyl or together form a moiety (CH 2 ) p with p being 2, 3, 4 or 5; and the physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula (I) or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D 3 receptor ligand.
摘要翻译：本发明涉及式（I）的芳族化合物，其中Ar是苯基或芳族5-或6-元C-结合杂芳族基团，其中Ar可以携带1个基团R 1

9. 发明申请

WO2006040176A1 AZABICYCLOHEPTYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR 审中-公开
标题翻译：适用于治疗多巴胺D3受体调节紊乱的化学物质
公开(公告)号：WO2006040176A1
公开(公告)日：2006-04-20
申请号：PCT/EP2005/011089
申请日：2005-10-14
申请人： ABBOTT GMBH & CO. KG , DRESCHER, Karla , HAUPT, Andreas , UNGER, Liliane , TURNER, Sean, C. , BRAJE, Wilfried , GRANDEL, Roland
发明人： DRESCHER, Karla , HAUPT, Andreas , UNGER, Liliane , TURNER, Sean, C. , BRAJE, Wilfried , GRANDEL, Roland
IPC分类号： C07D209/52 , C07D403/12 , C07D405/12 , C07D409/12 , A61K31/00 , A61P25/28
CPC分类号： C07D401/12 , C07D209/52 , C07D403/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/12
摘要： The present invention relates to a compound of the formula (I) wherein R 1 is H, C 1 -C 6 -alkyl which may be substituted by C 3 -C 6 -cycloalkyl, fluorinated C 1 -C 6 -alkyl, C 3 -C 6 -cycloalkyl, fluorinated C 3 -C 6 -cycloalkyl, C 3 -C 6 -alkenyl, fluorinated C 3 -C 6 -alkenyl, formyl, acetyl or propionyl; A is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one ore more substituents selected from halogen, methyl, methoxy and CF 3 ; E is NR 5 or CH 2 , wherein R 5 is H or C 1 -C 3 -alkyl; Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6-membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR 8 , where R 8 is H, C 1 -C 4 -alkyl, fluorinated C 1 -C 4 -alkyl, C 1 -C 4 -alkylcarbonyl or fluorinated C 1 -C 4 -alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents R a ; wherein the variable R a has the meanings given in the claims and in the description; and physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula (I) or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.
摘要翻译：本发明涉及式（I）化合物，其中R

10. 发明申请

WO2005118558A2 PYRIMIDINVERBINDUNGEN UND IHRE VERWENDUNG 审中-公开
标题翻译：嘧啶及其用途
公开(公告)号：WO2005118558A2
公开(公告)日：2005-12-15
申请号：PCT/EP2005/006000
申请日：2005-06-03
申请人： ABBOTT GMBH & CO. KG , GENESTE, Hervé , HAUPT, Andreas , BRAJE, Wilfried , LUBISCH, Wilfried , STEINER, Gerd , UNGER, Liliane
发明人： GENESTE, Hervé , HAUPT, Andreas , BRAJE, Wilfried , LUBISCH, Wilfried , STEINER, Gerd , UNGER, Liliane
IPC分类号： C07D239/00
CPC分类号： C07D417/12 , C07D401/12 , C07D413/12
摘要： Die vorliegende Erfindung betrifft neue Pyrimidin-Verbindungen der allgemeinen Formel (I), worin A für eine Gruppe C=W oder CR f R g steht; B für eine chemische Bindung oder eine Gruppe CR h R i steht; X für O, S, eine Gruppe N-R k oder eine Gruppe CR m R n steht; D für C=O oder eine chemische Bindung steht; E für eine lineare oder verzweigte 2 bis 10 gliedrige Alkylenkette steht, die als Kettenglieder 1 oder 2 nicht benachbarte Heteroatomgruppe(n) K aufweisen kann, die ausgewählt ist unter O, S, S(O), S(O) 2 und N-R p und die eine Carbonylgruppe und/oder eine Cycloalkandiyl-Gruppe umfassen kann und/oder eine Doppel- oder Dreifachbindung aufweisen kann; W Sauerstoff oder Schwefel bedeutet; Z gemeinsam mit den C-Atomen, an die es gebunden ist, einen kondensierten, gegebenenfalls substituierten 5-, 6- oder 7-gliedrigen Carbocyclus oder Heterocyclus, der 1, 2, 3 oder 4 Heteroatome aufweist, die ausgewählt sind unter N, O und S, bildet. J für CH 2, CH 2 -CH 2 oder CH 2 -CH 2 -CH 2 steht; M für CH oder N steht; Y für CH 2 , CH 2 -CH 2 oder CH 2 -CH 2 -CH 2 steht oder M-X gemeinsam CH=C oder CH 2 -CH=C bedeuten; n 0 oder 1 ist; und R a , R b , R c , R d , R e , R f , R g , R h , R i , R k , R p , R 1 , R 2 , R 3 , R 4 , R 5 und R 6 die in den Ansprüchen und in der Beschreibung angegebenen Bedeutungen aufweisen, und die physiologisch akzeptablen Säureadditionssalze dieser Verbindungen. Die vorliegende Erfindung betrifft auch die Verwendung dieser Verbindungen der allgemeinen Formel (I), sowie der physiologisch verträglichen Säureadditionssalze der Verbindungen I zur Herstellung eines pharmazeutischen Mittels zur Behandlung von Erkrankungen, die auf die Beeinflussung durch Dopamin-D 3 -Rezeptorantagonisten bzw. -agonisten ansprechen.
摘要翻译：本发明涉及通式（I），以及使用通式（I）的这些化合物的嘧啶化合物和所述化合物的生理学可接受的酸加成盐用于制备药物的用于治疗疾病的对多巴胺的影响响应响应-D3受体拮抗剂或激动剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式